Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Humira

AbbVie Delivers Strong Q1 Earnings Beyond Humira. This Dividend King Still Shines.

Q1 earnings show this Dividend King still looks built for the long term.

Barchart

7 Common Medications Affected by Midyear Pricing Shifts

We are trained to expect changes to our health insurance in January. We spend December reviewing Open Enrollment packets, selecting a plan, and budgeting for...

Saving Advice

AbbVie Stock: Analyst Estimates & Ratings

After Humira’s patent cliff, what do analysts think about AbbVie’s stock now?

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

8 Drug Ads Pulled After Massive Complaints

We have all seen them time and time again: the overly cheerful people jogging through parks, painting fences, or laughing over salads while a voice calmly lists horrifying side effects like “possible internal bleeding” and “sudden death.” Drug commercials are a strange blend of optimism and danger, and sometimes they…

Everybody Loves Your Money

The 5 Best Dividend Stocks to Buy for Steady Income in 2025

Here are five “set-and-forget” dividend stocks.

Barchart

AbbVie Stock Eyes Breakout as Pipeline and Profits Grow

AbbVie stock pops after strong Q2 earnings and raised guidance, as Skyrizi and Rinvoq offset Humira's decline and support a bullish outlook

MarketBeat

Don't Miss the Buying Opportunity in This Dividend King, Says Analyst

Leerink believes the recent selloff has made valuations attractive.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Humira, the world’s top-selling drug, faces an upcoming test from low cost alternatives

If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor.

Tribune News Service

Cheaper competition for Humira is hitting the market, but savings will depend on your insurance

Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July

The Independent UK

AbbVie's blockbuster drug Humira finally loses its 20-year, $200 billion monopoly

U.S. doctors can now choose Amjevita instead, the first of several close copies of the popular rheumatoid arthritis drug expected this year. But industry-watchers warn consumer savings may be limited.

WEKU

Good news for consumers, bad news for AbbVie as its blockbuster drug Humira faces competition

CHICAGO — One of the most popular prescription medications in the world is about to face fierce competition in the U.S. — something that could mean lower prices for the drug but a difficult coming year for the Illinois company that makes it.

Chicago Tribune

Morgan Stanley Upgrades Cigna On Humira Prospects

Cigna Corp (NYSE: CI) is poised to benefit from the launch of bioequivalent Humira in July 2023, according to Morgan Stanley.

Benzinga

AbbVie Shares Fall On Mixed Bag Q1 Results, Cuts FY22 Profit Guidance

AbbVie Inc (NYSE:ABBV) reports Q1 adjusted EPS of $3.16, higher than the $2.89 reported a year ago and beating the consensus of $3.14. Overall sales increased 4.1% Y/Y (5.4% on an operational basis) to $13.54 billion, missing the consensus of $13.63 billion. The immunology portfolio generated $6.14 billion in sales, +6.9% (+8.1%…

Benzinga

The Daily Biotech Pulse: Pfizer Begins Late-Stage Pediatric COVID Pill Study, Midatech And J&J Unit Expand R&D Collaboration, AbbVie-Alvotech Settle Humira Dispute

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Verizon Communications

89 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.